Unprecedented advances have been made in the treatment of cancer through the use of antibody against immune checkpoints, priming immune system instead of targeting cancer, with approval of several antibodies for multiple cancer types. However, so far we are merely seeing the tip of the iceberg because responses to this form of therapy are not universal. Next-generation antibody drug is needed. TIM-3 negatively regulates immune system and is one of the next generation targets. We have generated 13 clones of TIM-3 antibodies, potentially can be anti-tumor drug.